drugset / Trial / NCT05976321
A Study of TAK-279 in Adults With or Without Liver Damage
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to participants without liver problems. Other aims are to check for side effects from TAK-279 and to learn how well participants tolerate 1 dose of TAK-279. The participants will need to stay at the clinic for 11 days.
Timeline
- Start
- 2023-09-22
- Primary completion
- 2024-04-15
- Completion
- 2024-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zasocitinib | Small molecule | 50 mg | Oral |
Indications
No indication recorded.